Clete A. Kushida, M.D., Ph.D.
Academic Appointments
- Associate Professor - Med Center Line, Psychiatry & Behavioral Science - Sleep Center
Contact Information
-
Clinical Offices
Stanford Sleep Medicine Clinic 450 Broadway St Pavilion C, 2nd Flr Redwood City, CA 94063 Tel Work (650) 723-6601 Fax (650) 721-3465
Professional Snapshot
Clinical Focus
- Neurology
- Sleep Disorders
- Sleep Medicine
Administrative Appointments
- President, American Academy of Sleep Medicine (2009 - 2010)
- President, California Sleep Society (2008 - 2010)
- Secretary-Treasurer, American Academy of Sleep Medicine (2006 - 2009)
- Board Of Directors, American Academy of Sleep Medicine (2005 - 2011)
- Board Of Directors, American Board of Sleep Medicine (2000 - 2006) View All 10administrative appointments of Clete Kushida
Professional Education
| Board Certification: | Sleep Medicine, American Board of Sleep Medicine (1996) |
| Fellowship: | SUMC - Graduate Medical Education, CA (1996) |
| Residency: | UCSD Medical Center, CA (1994) |
| Internship: | University of Hawaii-J. A. Burns School of Medicine, HI (1991) |
| Medical Education: | University of Chicago Hospitals, IL (1990) |
Community & International Work
Web Site Links
Scientific Focus
Current Research Interests
Dr. Kushida is a neurologist and sleep specialist who directs several NIH- and industry-sponsored research studies, focused on topics such as the physical features and neurocognitive changes associated with the obstructive sleep apnea syndrome, the epidemiology and treatment of restless legs syndrome/periodic limb movement disorder, primary care sleep education and training, and countermeasures for sleep loss.
Clinical Trials
- A Clinical Research Study of MK-6096 for Primary Insomnia Recruiting
- Apnea Positive Pressure Long-Term Efficacy Study No longer recruiting
Publications
- Gabapentin enacarbil in restless legs syndrome: a phase 2b, 2-week, randomized, double-blind, placebo-controlled trial. Clin Neuropharmacol. 2009 Nov-Dec; (6): 311-20
- Primary hypersomnias of central origin. Semin Neurol. 2009; (4): 354-67
- Randomized, double-blind, placebo-controlled study of XP13512/GSK1838262 in patients with RLS. Neurology. 2009; (5): 439-46
- A randomized, double-blind, placebo-controlled, crossover study of XP13512/GSK1838262 in the treatment of patients with primary restless legs syndrome. Sleep. 2009; (2): 159-68
- Patient- and physician-rated measures demonstrate the effectiveness of ropinirole in the treatment of restless legs syndrome. Clin Neuropharmacol. 2008 Sep-Oct; (5): 281-6
Help